Shares of PDS Biotechnology Corp. (PDSB) are rising over 7% Monday morning, after the company announced robust preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203).
The company noted that PDS0203 pairs the Versamune platform with a recombinant protein recognized by the human immune system that is derived from the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19.
The protein included in PDS0203 encompasses SARS-CoV-2 sections that induce an antibody response, as well as sections that are recognized by CD8 and CD4 T-cells.
PDS Biotech has generated robust preclinical data confirming that PDS0203 elicits induction of highly active and potent virus-specific CD8 killer and CD4 helper T-cells within 14 days of treatment. Further, PDS Biotech said it plans to submit details of the preclinical studies to a peer reviewed scientific journal.
The stock has been trading in the range of $0.61 - $6.71 for the past one year, and is currently trading at $3.84, up 26 cents or 7.26%.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.